Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Long, SH; Berna, MJ; Thill, M; Pace, A; Pradhan, TK; Hoffmann, KM; Serrano, J; Jensen, RT.
Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.
J Clin Endocrinol Metab. 2007; 92(11): 4394-4402.
Doi: 10.1210/jc.2007-0986
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hoffmann Karl Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- CONTEXT/OBJECTIVES: The diagnosis of Zollinger-Ellison syndrome requires secretin testing in 60% of patients. Even with secretin, the diagnosis may be difficult because variable responses occur, and 6-30% have negative testing. The basis for variability or negative responses is unclear. It is unknown whether the tumor density of secretin receptors or the presence of a secretin-receptor-variant, which can act as a dominant negative, is important. The aim of this study was to investigate these possibilities. PATIENTS/METHODS: Secretin-receptor and variant mRNA expression was determined in gastrinomas using real-time PCR from 54 Zollinger-Ellison syndrome patients. Results were correlated with Western blotting, secretin-receptor immunohistochemistry, with gastrin-provocative test results and tumoral/clinical/laboratory features. RESULTS: Secretin-receptor mRNA was detectible in all gastrinomas but varied 132-fold with a mean of 0.89 +/- 0.12 molecules per beta-actin. Secretin-receptor PCR results correlated closely with Western blotting (r = 0.95; P < 0.0001) and receptor immunohistochemistry (P = 0.0015; r = 0.71). The variant was detected in all gastrinomas, but levels varied 102-fold and were 72-fold lower than the total. Secretin-receptor levels correlated with variant levels, Deltasecretin, but not Deltacalcium and with tumor location, but not growth, extent, or clinical responses. Variant levels did not correlate with the Deltasecretin. Detailed analysis provides no evidence that variant expression modified the secretin-receptor response or accounted for negative tests. CONCLUSIONS: Secretin-receptor and secretin-receptor-variant expressions occur in all gastrinomas. Because the expression of the total, but not variant, correlated with the secretin results and no evidence for dominant negative activity of the variant was found, our results suggest that the total secretin-receptor density is an important determinant of the secretin test response.
- Find related publications in this database (using NLM MeSH Indexing)
- Blotting, Western -
- Calcium - metabolism
- DNA, Complementary - genetics
- Female - genetics
- Gastrinoma - genetics
- Gene Expression Regulation - physiology
- Humans - physiology
- Immunohistochemistry - physiology
- Male - physiology
- Middle Aged - physiology
- Multiple Endocrine Neoplasia Type 1 - genetics
- Pancreatic Neoplasms - genetics
- RNA, Messenger - biosynthesis
- Receptors, G-Protein-Coupled - genetics
- Receptors, Gastrointestinal Hormone - genetics
- Reverse Transcriptase Polymerase Chain Reaction - genetics
- Zollinger-Ellison Syndrome - genetics